Nature Communications (Apr 2025)

Mutant huntingtin induces neuronal apoptosis via derepressing the non-canonical poly(A) polymerase PAPD5

  • Zhefan Stephen Chen,
  • Shaohong Isaac Peng,
  • Lok I Leong,
  • Terence Gall-Duncan,
  • Nathan Siu Jun Wong,
  • Tsz Ho Li,
  • Xiao Lin,
  • Yuming Wei,
  • Alex Chun Koon,
  • Junzhe Huang,
  • Jacquelyne Ka-Li Sun,
  • Clinton Turner,
  • Lynette Tippett,
  • Maurice A. Curtis,
  • Richard L. M. Faull,
  • Kin Ming Kwan,
  • Hei-Man Chow,
  • Ho Ko,
  • Ting-Fung Chan,
  • Kevin Talbot,
  • Christopher E. Pearson,
  • Ho Yin Edwin Chan

DOI
https://doi.org/10.1038/s41467-025-58618-4
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 18

Abstract

Read online

Abstract MicroRNAs (miRNAs) are small non-coding RNAs that play crucial roles in post-transcriptional gene regulation. Poly(A) RNA polymerase D5 (PAPD5) catalyzes the addition of adenosine to the 3′ end of miRNAs. In this study, we demonstrate that the Yin Yang 1 protein, a transcriptional repressor of PAPD5, is recruited to both RNA foci and protein aggregates, resulting in an upregulation of PAPD5 expression in Huntington’s disease (HD). Additionally, we identify a subset of PAPD5-regulated miRNAs with increased adenylation and reduced expression in our disease model. We focus on miR-7-5p and find that its reduction causes the activation of the TAB2-mediated TAK1–MKK4–JNK pro-apoptotic pathway. This pathway is also activated in induced pluripotent stem cell-derived striatal neurons and post-mortem striatal tissues isolated from HD patients. In addition, we discover that a small molecule PAPD5 inhibitor, BCH001, can mitigate cell death and neurodegeneration in our disease models. This study highlights the importance of PAPD5-mediated miRNA dysfunction in HD pathogenesis and suggests a potential therapeutic direction for the disease.